Welcome to AiCuris: The Powerhouse for Anti-Infectives

AiCuris (from 'Anti-infective Cures') is a pharmaceutical company focused exclusively on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.   Founded in 2006 from Bayer's virology and bacteriology research divisions, AiCuris today has an innovative pipeline of novel anti-infectives and a team of internationally regarded scientists and drug developers. With its tight focus on specialist markets with high medical need, the company is perfectly positioned for growth and success.

     

AiCuris-Team receives German Future Prize  /  AiCuris-Team mit dem Deutschen Zukunftspreis ausgezeichnet

 

Read more...

Deutscher Innovationspreis 2019

AiCuris nominated for “Deutscher Innovationspreis 2019”
  • AiCuris Anti-infective Cures GmbH is one of three companies nominated for the “Deutscher Innovationspreis 2019” in the category Medium-Sized Enterprises
  • Nomination for the development of Letermovir, the world's first and only drug to prevent infections from a common virus in bone marrow transplant patients, that represents a paradigm shift in the field of transplantation medicine

  Read more ...

Cooperation with Cyclenium

AiCuris to cooperate with Cyclenium Pharma to Develop Novel Anti-Infectives

AiCuris and Cyclenium announced today the signing of a collaboration agreement focused on finding new pharmaceutical compounds for the treatment and prevention of bacterial and viral diseases.

 

 

 

Read more ... 

Job Opportunities

Join AiCuris and its quest for novel Anti-Infectives

We offer an exciting and challenging working enviroment in an innovative company with a world-class  R&D Portfolio. 

  

 

 

 

 

 Read more ...